Biotech Scan
Biotech Scan
Broad biotech weakness continues — LEGN still at RSI 7.5 (third consecutive week of capitulation), BNTX and ALNY pulled back sharply, while EDIT surged +16% 7D on speculative momentum; large pharma defensive with JNJ/ABBV holding above SMA.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 MIXED/WEAK — Gene editing recovery stalled, RNAi fading, mRNA holding gains; large pharma mostly stable |
| Leaders | ABBV (RSI 63, +2.3% 7D), JNJ (RSI 66, +6.4% 30D), MRNA (RSI 61, above SMA) |
| Laggards | LEGN (RSI 7.5, -27.1% 30D), BNTX (-9.1% 7D), ALNY (-4.3% 7D, RSI 36) |
Price Table (2026-03-03)
| Stock | Price | RSI | SMA20 | vs SMA | 7D% | 30D% | Signal |
|---|---|---|---|---|---|---|---|
| CRSP | $58.04 | 56 | $53.35 | +8.8% | +2.2% | +15.7% | 🟡 Extended |
| BEAM | $28.38 | 62 | $27.76 | +2.2% | +1.8% | -8.3% | 🟡 Neutral |
| EDIT | $2.10 | 74 | $1.88 | +11.7% | +16.0% | +1.9% | 🟠 Near Overbought |
| NTLA | $13.60 | 54 | $12.82 | +6.1% | +0.1% | +10.0% | 🟡 Neutral |
| ALNY | $318.65 | 37 | $329.48 | -3.3% | -4.3% | -9.5% | 🟡 Weak |
| LEGN | $17.20 | 7.5 | $19.40 | -11.3% | +0.3% | -27.1% | 🔴 Capitulation |
| MRNA | $49.84 | 61 | $46.20 | +7.9% | -1.3% | +16.5% | 🟠 Near Overbought |
| BNTX | $100.76 | 36 | $108.14 | -6.8% | -9.1% | -7.4% | 🟡 Weak |
| LLY | $1,007.30 | 47 | $1,032.85 | -2.5% | -3.3% | +0.6% | 🟡 Below SMA |
| GILD | $147.79 | 54 | $149.93 | -1.4% | +0.1% | +1.1% | 🟡 Neutral |
| BIIB | $184.02 | 46 | $191.14 | -3.7% | -5.7% | -0.8% | 🟡 Weak |
| VRTX | $474.27 | 50 | $475.37 | -0.2% | -2.7% | +0.8% | 🟡 Neutral |
| ABBV | $233.59 | 63 | $226.55 | +3.1% | +2.3% | +3.5% | 🟢 Strong |
| PFE | N/A | N/A | N/A | — | — | — | — |
| JNJ | $246.71 | 66 | $241.78 | +2.0% | +0.2% | +6.4% | 🟢 Strong |
| BMY | N/A | N/A | N/A | — | — | — | — |
| REGN | $766.66 | 48 | $778.87 | -1.6% | -0.7% | -1.0% | 🟡 Neutral |
| AMGN | $377.00 | 57 | $372.97 | +1.1% | -1.5% | +3.7% | 🟡 Neutral |
Tier Analysis
Capitulation (RSI < 25)
LEGN RSI 7.5 — Third consecutive week in extreme oversold. No bounce has materialized despite multiple low-RSI readings. This is company-specific breakdown, not sector contagion. Risk of continued deterioration. Avoid unless you have strong thesis conviction.
Oversold (RSI 25–40)
ALNY RSI 37 — Pulled back from RSI 49 last scan, now -3.3% below SMA. The RNAi thesis is intact but momentum has reversed from the prior recovery. $310-$325 zone is a potential re-entry if RSI stabilizes. BNTX RSI 36 — Sharp -9.1% 7D drop pushes it back below SMA (-6.8%). mRNA sector enthusiasm fading. Watch for RSI < 30 as better entry.
Neutral (RSI 40–60)
LLY RSI 47 — GLP-1 king continues to drift below SMA (-2.5%). Thesis intact long-term but near-term compression. $990-$1,010 zone remains key. BIIB RSI 46 — Cooling from prior strength, -3.7% below SMA, -5.7% 7D. Healthy decompression. GILD RSI 54, VRTX RSI 50, REGN RSI 48, AMGN RSI 57 — All stable near SMA, no urgent signals. CRSP RSI 56 — +8.8% above SMA after +15.7% 30D run; extended, not chasing. NTLA RSI 54 — Quietly recovered +10% 30D, above SMA.
Strong / Extended (RSI 60+)
EDIT RSI 74 — +16% 7D is likely speculative squeeze, not fundamental. At RSI 74 and +11.7% above SMA, this is a momentum trade, not an entry. ABBV RSI 63 — Legitimate strength, above SMA, +2.3% 7D. Defensive large pharma holding well. JNJ RSI 66 — Defensive leader, above SMA, +6.4% 30D. MRNA RSI 61 — Holding +7.9% above SMA despite slight 7D fade. Prior momentum intact but cooling.
Entry Zones
| Stock | Entry Zone | RSI Trigger | Thesis |
|---|---|---|---|
| 🟡 ALNY | $310–$325 | RSI < 35 | RNAi leader, pulled back from recovery; watch for RSI stabilization |
| 🟡 BNTX | $95–$105 | RSI < 32 | mRNA platform, -6.8% below SMA; let RSI exhaust further |
| 🟡 LLY | $990–$1,010 | RSI < 45 | GLP-1 dominant franchise, near-term SMA compression |
| 🟡 BIIB | $180–$190 | RSI < 42 | Alzheimer's pipeline, cooling from strength |
| 🟡 VRTX | $465–$475 | RSI < 47 | CF monopoly, near SMA; steady accumulate zone |
| 🔴 LEGN | Avoid | — | RSI 7.5 three consecutive weeks — broken, high risk |
| ⚠️ EDIT | Avoid | — | RSI 74, speculative squeeze, no fundamental catalyst |
| ⚠️ MRNA | Avoid | — | RSI 61, extended above SMA — do not chase |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 🔒 HOLD | ABBV, JNJ, AMGN, GILD | Above SMA, defensive strength, stable RSI |
| 🔍 WATCH | ALNY, BNTX, LLY, BIIB, VRTX | Approaching or in entry zones; wait for RSI confirmation |
| 🔍 WATCH | NTLA, CRSP | Recovered above SMA but extended; don't add here |
| ⚠️ AVOID | EDIT | RSI 74, +16% 7D — momentum squeeze, not fundamental |
| ⚠️ AVOID | MRNA | RSI 61 and above SMA — do not chase prior 30D run |
| ❌ DON'T BUY | LEGN | RSI 7.5 for third week — falling knife, broken thesis |
| — | PFE, BMY | No data available |
What Changed (vs 2026-02-26)
| Stock | Prev RSI | Curr RSI | Prev Price | Curr Price | Move | Note |
|---|---|---|---|---|---|---|
| LEGN | ~8 | 7.5 | $17.20 | $17.20 | Flat | Third week at capitulation, no bounce |
| ALNY | 49 | 37 | $336 | $318.65 | -5.2% | Recovery reversed, back to weak territory |
| BNTX | ~43 | 36 | $110 | $100.76 | -8.4% | Sharp pullback, approaching oversold |
| MRNA | 67 | 61 | $49.87 | $49.84 | Flat | Holding gain but momentum fading |
| EDIT | 35 | 74 | $1.76 | $2.10 | +19% | Speculative surge, RSI spiked |
| CRSP | 58 | 56 | $53.46 | $58.04 | +8.6% | Continued run, +8.8% above SMA |
Key Discoveries
| Discovery | Implication |
|---|---|
| LEGN RSI 7.5 for 3rd consecutive week with no bounce | Structural breakdown — requires thesis re-evaluation before any entry |
| ALNY reversed from RSI 49 back to 37 | RNAi recovery was not sustained; patience required, better entry coming |
| EDIT +16% 7D with RSI surging to 74 | Speculative squeeze on low-float biotech — avoid, not fundamental |
| ABBV and JNJ both RSI 63-66, above SMA | Large pharma defensive rotation holding — flight to quality within biotech |
Open Questions
- What is driving EDIT's +16% surge? Pipeline data or short squeeze?
- LEGN: Has competitive pressure from J&J's carvykti overtaken ciltacabtagene ciloleucel market share permanently?
- Will BNTX find support at $95 or continue to RSI 25?
- LLY at $990: Is the GLP-1 premium compression temporary or structural?
Related
10 eventsNo direct external sources are attached to this read.